PH12015501096A1 - Composition for immediate and extended release - Google Patents

Composition for immediate and extended release

Info

Publication number
PH12015501096A1
PH12015501096A1 PH12015501096A PH12015501096A PH12015501096A1 PH 12015501096 A1 PH12015501096 A1 PH 12015501096A1 PH 12015501096 A PH12015501096 A PH 12015501096A PH 12015501096 A PH12015501096 A PH 12015501096A PH 12015501096 A1 PH12015501096 A1 PH 12015501096A1
Authority
PH
Philippines
Prior art keywords
immediate
composition
extended release
active ingredient
controlled release
Prior art date
Application number
PH12015501096A
Other languages
English (en)
Inventor
Ahuja Varinder
Verma Rajan
Barabde Umesh Vinayakrao
Hagsten Arne
Wannerberger Kristin
Boorugu Rambabu
Somwanshi Amol Vilasrao
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of PH12015501096A1 publication Critical patent/PH12015501096A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PH12015501096A 2012-11-21 2015-05-15 Composition for immediate and extended release PH12015501096A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN3575DE2012 2012-11-21
IN3947DE2012 2012-12-20
PCT/EP2013/074373 WO2014079922A1 (en) 2012-11-21 2013-11-21 Composition for immediate and extended release

Publications (1)

Publication Number Publication Date
PH12015501096A1 true PH12015501096A1 (en) 2015-07-27

Family

ID=49619947

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12015501096A PH12015501096A1 (en) 2012-11-21 2015-05-15 Composition for immediate and extended release

Country Status (18)

Country Link
EP (1) EP2922525A1 (enrdf_load_stackoverflow)
JP (1) JP2016500088A (enrdf_load_stackoverflow)
KR (1) KR20150085826A (enrdf_load_stackoverflow)
CN (1) CN104797240A (enrdf_load_stackoverflow)
AR (1) AR093585A1 (enrdf_load_stackoverflow)
AU (1) AU2013349682A1 (enrdf_load_stackoverflow)
BR (1) BR112015011430A2 (enrdf_load_stackoverflow)
CA (1) CA2891365A1 (enrdf_load_stackoverflow)
EA (1) EA201590805A1 (enrdf_load_stackoverflow)
HK (1) HK1213779A1 (enrdf_load_stackoverflow)
IL (1) IL238648A0 (enrdf_load_stackoverflow)
IN (1) IN2015DN03984A (enrdf_load_stackoverflow)
MX (1) MX2015006399A (enrdf_load_stackoverflow)
PH (1) PH12015501096A1 (enrdf_load_stackoverflow)
SG (2) SG11201503913TA (enrdf_load_stackoverflow)
TW (1) TW201422254A (enrdf_load_stackoverflow)
WO (1) WO2014079922A1 (enrdf_load_stackoverflow)
ZA (1) ZA201503603B (enrdf_load_stackoverflow)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210103589A (ko) 2013-07-23 2021-08-23 세레니티 파마슈티컬즈 엘엘씨 베타-3-아드레날린 수용체 작용제와 함께 데스모프레신을 포함하는 방법 및 조성물
KR20150144209A (ko) * 2014-06-16 2015-12-24 훼링 비.브이. 안정화된 데스모프레신 또는 이의 약학적으로 허용가능한 염을 함유 약학 조성물
WO2016081772A1 (en) * 2014-11-20 2016-05-26 Allergan, Inc. Methods and compositions comprising desmopressin in combination with an alpha-adrenergic receptor antagonist
BR112017014953A2 (pt) 2015-01-12 2018-03-13 Nano Pharmaceutical Laboratories Llc microglóbulos de liberação controlada em camadas e métodos para produção dos mesmos
WO2016174664A1 (en) 2015-04-29 2016-11-03 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
EP3344240A4 (en) * 2015-09-01 2019-09-04 Wellesley Pharmaceuticals, LLC FORMULATION WITH EXTENDED, DELAYED AND IMMEDIATE RELEASE, METHOD FOR THE PRODUCTION AND USE THEREOF
AU2016331871A1 (en) * 2015-09-30 2018-05-17 Wellesley Pharmaceuticals, Llc Composition for reducing the frequency of urination, method of making and use thereof
CN108430465A (zh) * 2015-09-30 2018-08-21 韦尔斯利医药有限公司 用于缓解尿频的组合物、其制造方法和用途
TW201726114A (zh) * 2015-11-23 2017-08-01 魏斯理製藥公司 降低排尿頻率之組成物、其製備方法、及其應用
CA3008628A1 (en) * 2015-12-18 2017-06-22 Wellesley Pharmaceuticals, Llc Composition for reducing frequency of urination, method of making and use thereof
CA3018285C (en) 2016-04-21 2024-02-27 Valcuria Ab Composition and method for pretreating cancer
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
CA3046725A1 (en) * 2017-01-11 2018-07-19 Ferring B.V. A fast disintegrating pharmaceutical composition
WO2019039836A2 (ko) * 2017-08-22 2019-02-28 아주대학교산학협력단 퇴행성 신경질환 치료용 복합 제형 조성물
US12389928B1 (en) * 2024-10-25 2025-08-19 Mccormick & Company, Inc. Flavor-changing product

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998003184A1 (en) 1996-07-19 1998-01-29 Clarke-Garegg, Margaret, A. Levan derivatives, their preparation, composition and applications including medical and food applications
SE9803871D0 (sv) 1998-11-11 1998-11-11 Pharmacia & Upjohn Ab Therapeutic method and formulation
GB9908014D0 (en) 1999-04-08 1999-06-02 Scherer Corp R P Pharmaceutical compositions
EP1064938A1 (en) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Pharmaceutical dosage forms for controlled release producing at least a timed pulse
US6509040B1 (en) 2001-06-22 2003-01-21 R.P. Scherer Corporation Fast dispersing dosage forms essentially free of mammalian gelatin
DE60307082T4 (de) * 2002-05-07 2015-04-30 Ferring B.V. In der mundhöhle dispergierbare phamarzeutische zusammensetzung mit desmopressin
GB0210397D0 (en) 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
US8012505B2 (en) 2003-02-28 2011-09-06 Alk-Abello A/S Dosage form having a saccharide matrix
CN100366294C (zh) 2004-04-30 2008-02-06 量子高科（北京）研究院有限公司 一种口腔速溶制剂及其生产方法
EP1629834A1 (en) 2004-08-27 2006-03-01 KRKA, D.D., Novo Mesto Sustained release pharmaceutical composition of tolterodine
WO2007029087A2 (en) 2005-09-05 2007-03-15 Ranbaxy Laboratories Limited Controlled release multiple unit formulations
US20090192228A1 (en) 2008-01-28 2009-07-30 Actavis Group Ptc Ehf Controlled-Release Tolterodine Compositions and Methods
KR20110075011A (ko) * 2008-11-10 2011-07-05 (주)아모레퍼시픽 서방성 미립자 및 이의 제조방법
US9078830B2 (en) * 2009-07-31 2015-07-14 Ranbaxy Laboratories Limited Multi-layered, multiple unit pharmaceutical compositions
JO3112B1 (ar) 2010-03-29 2017-09-20 Ferring Bv تركيبة دوائية سريعة التحلل
RU2566269C2 (ru) 2010-03-29 2015-10-20 Ферринг Б.В. Быстрорастворимая фармацевтическая композиция
MX356601B (es) * 2010-03-30 2018-05-29 Productos Maver S A De C V Combinación farmacéutica con efecto antimigrañoso, en presentación sólida de liberación diferenciada.
US20120135050A1 (en) * 2010-07-08 2012-05-31 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof

Also Published As

Publication number Publication date
EA201590805A1 (ru) 2015-11-30
ZA201503603B (en) 2016-01-27
EP2922525A1 (en) 2015-09-30
CN104797240A (zh) 2015-07-22
JP2016500088A (ja) 2016-01-07
AU2013349682A1 (en) 2015-06-04
IL238648A0 (en) 2015-06-30
BR112015011430A2 (pt) 2017-07-11
TW201422254A (zh) 2014-06-16
IN2015DN03984A (enrdf_load_stackoverflow) 2015-10-02
WO2014079922A1 (en) 2014-05-30
SG10201703388TA (en) 2017-05-30
MX2015006399A (es) 2015-07-21
SG11201503913TA (en) 2015-06-29
KR20150085826A (ko) 2015-07-24
HK1213779A1 (zh) 2016-07-15
CA2891365A1 (en) 2014-05-30
AR093585A1 (es) 2015-06-10

Similar Documents

Publication Publication Date Title
PH12015501096A1 (en) Composition for immediate and extended release
IL244206A0 (en) A pharmaceutical preparation containing a pyrimidine compound as an active ingredient
MX2015008627A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2021000550A (es) Forma de dosis orales de liberacion sostenida de tofacitinib.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
EP2917180A4 (en) GPR40 RECEPTOR AGONIST, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE SUBSTANCE
EP3082817A4 (en) Compositions for drug administration
MX2015008628A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
IL236057B (en) History of 4,2,1-triazine-6-carboxamide and pharmaceutical preparations containing them
IL232973B (en) Pharmaceutical preparations containing micelles containing a chelator complex for controlled drug release and uses thereof
MY168212A (en) A new therapeutical composition containing apomorphine as active ingredient
PT3003285T (pt) Forma de administração farmacêutica sólida para libertação de pelo menos dois princípios ativos farmacêuticos na cavidade oral
ZA201505318B (en) 2-substituted-6-biarylmethylamino-9-cyclopentyl-9h-purine derivatives, use thereof as medicaments, and pharmaceutical compositions
MX2016001422A (es) Composicion farmaceutica de fingolimod.
HUE050945T2 (hu) Gyógyszerforma hatóanyagok nyújtott felszabadítására
IL240666A0 (en) Pharmaceutical preparations for oral administration and their uses
PT2846839T (pt) Formulações para a administração de ingredientes ativos
IL236466B (en) Pharmaceutical composition for the release of active components
ZA201505196B (en) Topical ophthalmological pharmaceutical composition containing regorafenib
IL206739A (en) An injectable drug containing silitol as an active substance
IL239670B (en) Monolithic administration form for delayed release of a combination of active substances
PL2953617T3 (pl) Kompozycje farmaceutyczne zawierające leki w małej dawce
MX2012014969A (es) Composiciones farmaceuticas estables de amlodipina con telmisartan.
IN2013CH02437A (enrdf_load_stackoverflow)